DDInter895 DDInter1676
Hydroxyzine is a first-generation histamine H<sub>1</sub>-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties.[A1257,A187589] It was first developed in 1955, and has since remained a relatively common treatment for allergic conditions such as pruritus, urticaria, dermatoses, and histamine-mediated pruritus. The active metabolite of hydroxyzine, [cetirizine], is also available as an active ingredient in allergic medications, and is responsible for much of its hydroxyzine's antihistaminic effect. Hydroxyzine is also used for generalized anxiety disorder, tension caused by psychoneurosis, and other conditions with manifestations of anxiety.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Hydroxyzine {u} (Compound) resembles {v} (Compound) Anileridine
Hydroxyzine {u} (Compound) resembles {v} (Compound) Quetiapine
Hydroxyzine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cyclizine
Hydroxyzine {u} (Compound) binds {v} (Gene) HRH1
Hydroxyzine {u} (Compound) is included by {v} (Pharmacologic Class) Histamine Receptor Antagonists
Hydroxyzine {u} (Compound) causes {v} (Side Effect) Drowsiness
Hydroxyzine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cimetidine
Hydroxyzine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Hyaluronidase
Hydroxyzine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Terfenadine
Hydroxyzine {u} may lead to a major life threatening interaction when taken with {v} Macimorelin
Hydroxyzine (Compound) resembles Anileridine (Compound)
Hydroxyzine (Compound) resembles Quetiapine (Compound)
Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine
Hydroxyzine (Compound) binds HRH1 (Gene)
Hydroxyzine (Compound) is included by Histamine Receptor Antagonists (Pharmacologic Class)
Hydroxyzine (Compound) causes Drowsiness (Side Effect)
Hydroxyzine may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Hydroxyzine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase
Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine
Hydroxyzine may lead to a major life threatening interaction when taken with Macimorelin